VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Postoperative EGFR-TKI Therapy
Phase 2
Small molecule
S
Sun Yat-sen University
1
Indications
3
Total Trials
2
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Pulmonary Nodules
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Pulmonary Nodules
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Locally Advanced Colon Cancer
1 trial
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
Active, not recruiting
·
S
Sun Yat-sen University
·
Phase 3
·
NCT02572141
·
738 enrolled
Infection Prevention
1 trial
Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
Suspended
·
S
Sun Yat-sen University
·
Phase 3
·
NCT03990974
·
458 enrolled
Pulmonary Nodules
1 trial
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Recruiting
·
S
Sun Yat-sen University
·
Phase 2
·
NCT06924398
·
32 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for Postoperative EGFR-TKI Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Postoperative EGFR-TKI Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Postoperative EGFR-TKI Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
S
Sun Yat-sen University
Related News